How much profit has Dae Hwa Pharm Co made this year?
Dae Hwa Pharm Co has made -1.15 B KRW this year.
Dae Hwa Pharm Co Net Income 2024
Dae Hwa Pharm Co Net Income
-1.15 B KRW
Ticker
067080.KQ
ISIN
KR7067080002
In 2024, Dae Hwa Pharm Co's profit amounted to -1.15 B KRW, a -202.79% increase from the 1.12 B KRW profit recorded in the previous year.
The Dae Hwa Pharm Co Net Income history
| YEAR | NET INCOME (undefined KRW) |
|---|---|
| 2023 | -1.15 |
| 2022 | 1.12 |
| 2021 | 2.22 |
| 2020 | -2.01 |
| 2019 | 10.54 |
| 2018 | 6.65 |
| 2017 | 12.65 |
| 2016 | 3.73 |
| 2015 | 3.91 |
| 2014 | -0.1 |
| 2013 | 1.68 |
| 2012 | 3.15 |
| 2011 | 3.37 |
| 2010 | 4.53 |
| 2009 | 4.01 |
| 2008 | 2.01 |
| 2007 | 3.42 |
| 2006 | 3.06 |
| 2005 | 2.88 |
| 2004 | 2.26 |
Dae Hwa Pharm Co Revenue, EBIT, Net Income KR7067080002 ·
3 years
5 years
10 years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Dae Hwa Pharm Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Dae Hwa Pharm Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Dae Hwa Pharm Co’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Dae Hwa Pharm Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Dae Hwa Pharm Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Dae Hwa Pharm Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Dae Hwa Pharm Co’s growth potential.
Dae Hwa Pharm Co Revenue, EBIT and net profit per share
| Date | Dae Hwa Pharm Co Revenue | Dae Hwa Pharm Co EBIT | Dae Hwa Pharm Co Net Income |
|---|---|---|---|
| 2023 | 141.36 B undefined | 1.82 B undefined | -1.15 B undefined |
| 2022 | 131.91 B undefined | 5.7 B undefined | 1.12 B undefined |
| 2021 | 117.16 B undefined | 3.14 B undefined | 2.22 B undefined |
| 2020 | 109.35 B undefined | 3.8 B undefined | -2.01 B undefined |
| 2019 | 114.61 B undefined | 6.08 B undefined | 10.54 B undefined |
| 2018 | 110.14 B undefined | 5.03 B undefined | 6.65 B undefined |
| 2017 | 122.2 B undefined | 8.36 B undefined | 12.65 B undefined |
| 2016 | 142.29 B undefined | 5.32 B undefined | 3.73 B undefined |
| 2015 | 139.08 B undefined | 5.59 B undefined | 3.91 B undefined |
| 2014 | 134.93 B undefined | 4.45 B undefined | -102 M undefined |
| 2013 | 128 B undefined | 4.56 B undefined | 1.68 B undefined |
| 2012 | 143.17 B undefined | 8.1 B undefined | 3.15 B undefined |
| 2011 | 142.04 B undefined | 8.78 B undefined | 3.37 B undefined |
| 2010 | 98.2 B undefined | 10.39 B undefined | 4.53 B undefined |
| 2009 | 57.47 B undefined | 6.72 B undefined | 4.01 B undefined |
| 2008 | 48.38 B undefined | 5.76 B undefined | 2.01 B undefined |
| 2007 | 46.3 B undefined | 6.38 B undefined | 3.42 B undefined |
| 2006 | 37.58 B undefined | 4.45 B undefined | 3.06 B undefined |
| 2005 | 33.92 B undefined | 4.08 B undefined | 2.88 B undefined |
| 2004 | 28.55 B undefined | 3.31 B undefined | 2.26 B undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 28.55 B KRW | 3.31 B KRW | 2.26 B KRW |
| 2005 | 33.92 B KRW | 4.08 B KRW | 2.88 B KRW |
| 2006 | 37.58 B KRW | 4.45 B KRW | 3.06 B KRW |
| 2007 | 46.3 B KRW | 6.38 B KRW | 3.42 B KRW |
| 2008 | 48.38 B KRW | 5.76 B KRW | 2.01 B KRW |
| 2009 | 57.47 B KRW | 6.72 B KRW | 4.01 B KRW |
| 2010 | 98.2 B KRW | 10.39 B KRW | 4.53 B KRW |
| 2011 | 142.04 B KRW | 8.78 B KRW | 3.37 B KRW |
| 2012 | 143.17 B KRW | 8.1 B KRW | 3.15 B KRW |
| 2013 | 128 B KRW | 4.56 B KRW | 1.68 B KRW |
| 2014 | 134.93 B KRW | 4.45 B KRW | -102 M KRW |
| 2015 | 139.08 B KRW | 5.59 B KRW | 3.91 B KRW |
| 2016 | 142.29 B KRW | 5.32 B KRW | 3.73 B KRW |
| 2017 | 122.2 B KRW | 8.36 B KRW | 12.65 B KRW |
| 2018 | 110.14 B KRW | 5.03 B KRW | 6.65 B KRW |
| 2019 | 114.61 B KRW | 6.08 B KRW | 10.54 B KRW |
| 2020 | 109.35 B KRW | 3.8 B KRW | -2.01 B KRW |
| 2021 | 117.16 B KRW | 3.14 B KRW | 2.22 B KRW |
| 2022 | 131.91 B KRW | 5.7 B KRW | 1.12 B KRW |
| 2023 | 141.36 B KRW | 1.82 B KRW | -1.15 B KRW |
Dae Hwa Pharm Co stock margins KR7067080002 ·
The Dae Hwa Pharm Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Dae Hwa Pharm Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Dae Hwa Pharm Co.
3 years
5 years
10 years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Dae Hwa Pharm Co's sales revenue. A higher gross margin percentage indicates that the Dae Hwa Pharm Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Dae Hwa Pharm Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Dae Hwa Pharm Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Dae Hwa Pharm Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Dae Hwa Pharm Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Dae Hwa Pharm Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Dae Hwa Pharm Co Margin History
| Dae Hwa Pharm Co Gross margin | Dae Hwa Pharm Co Profit margin | Dae Hwa Pharm Co EBIT margin | Dae Hwa Pharm Co Profit margin |
|---|---|---|---|
| 2023 | 32.12 % | 1.28 % | -0.81 % |
| 2022 | 34.95 % | 4.32 % | 0.85 % |
| 2021 | 37.28 % | 2.68 % | 1.89 % |
| 2020 | 39.11 % | 3.47 % | -1.84 % |
| 2019 | 42.43 % | 5.3 % | 9.2 % |
| 2018 | 41.61 % | 4.56 % | 6.04 % |
| 2017 | 37.91 % | 6.84 % | 10.36 % |
| 2016 | 31.32 % | 3.74 % | 2.62 % |
| 2015 | 30.41 % | 4.02 % | 2.81 % |
| 2014 | 29.26 % | 3.3 % | -0.08 % |
| 2013 | 25.53 % | 3.56 % | 1.31 % |
| 2012 | 25.37 % | 5.65 % | 2.2 % |
| 2011 | 25.8 % | 6.18 % | 2.37 % |
| 2010 | 38.3 % | 10.58 % | 4.61 % |
| 2009 | 49.42 % | 11.69 % | 6.97 % |
| 2008 | 55.39 % | 11.91 % | 4.15 % |
| 2007 | 56.8 % | 13.78 % | 7.38 % |
| 2006 | 63.95 % | 11.84 % | 8.13 % |
| 2005 | 62.41 % | 12.01 % | 8.49 % |
| 2004 | 59.79 % | 11.61 % | 7.9 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 59.79 % | 11.61 % | 7.9 % |
| 2005 | 62.41 % | 12.01 % | 8.49 % |
| 2006 | 63.95 % | 11.84 % | 8.13 % |
| 2007 | 56.8 % | 13.78 % | 7.38 % |
| 2008 | 55.39 % | 11.91 % | 4.15 % |
| 2009 | 49.42 % | 11.69 % | 6.97 % |
| 2010 | 38.3 % | 10.58 % | 4.61 % |
| 2011 | 25.8 % | 6.18 % | 2.37 % |
| 2012 | 25.37 % | 5.65 % | 2.2 % |
| 2013 | 25.53 % | 3.56 % | 1.31 % |
| 2014 | 29.26 % | 3.3 % | -0.08 % |
| 2015 | 30.41 % | 4.02 % | 2.81 % |
| 2016 | 31.32 % | 3.74 % | 2.62 % |
| 2017 | 37.91 % | 6.84 % | 10.36 % |
| 2018 | 41.61 % | 4.56 % | 6.04 % |
| 2019 | 42.43 % | 5.3 % | 9.2 % |
| 2020 | 39.11 % | 3.47 % | -1.84 % |
| 2021 | 37.28 % | 2.68 % | 1.89 % |
| 2022 | 34.95 % | 4.32 % | 0.85 % |
| 2023 | 32.12 % | 1.28 % | -0.81 % |
Dae Hwa Pharm Co Aktienanalyse
What does Dae Hwa Pharm Co do?
Dae Hwa Pharm Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Dae Hwa Pharm Co's Profit Margins
The profit margins of Dae Hwa Pharm Co represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Dae Hwa Pharm Co's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Dae Hwa Pharm Co's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Dae Hwa Pharm Co's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Dae Hwa Pharm Co’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Dae Hwa Pharm Co stock
How has the profit developed compared to last year?
The profit has increased by -202.79% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Dae Hwa Pharm Co publish its earnings?
Dae Hwa Pharm Co publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Dae Hwa Pharm Co?
The profits of Dae Hwa Pharm Co are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Dae Hwa Pharm Co?
You can learn more about the earnings of Dae Hwa Pharm Co by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Dae Hwa Pharm Co pay?
Over the past 12 months, Dae Hwa Pharm Co paid a dividend of 150 KRW . This corresponds to a dividend yield of about 1.37 %. For the coming 12 months, Dae Hwa Pharm Co is expected to pay a dividend of 150 KRW.
What is the dividend yield of Dae Hwa Pharm Co?
The current dividend yield of Dae Hwa Pharm Co is 1.37 %.
When does Dae Hwa Pharm Co pay dividends?
Dae Hwa Pharm Co pays a quarterly dividend. This is distributed in the months of July, January, July, January.
How secure is the dividend of Dae Hwa Pharm Co?
Dae Hwa Pharm Co paid dividends every year for the past 20 years.
What is the dividend of Dae Hwa Pharm Co?
For the upcoming 12 months, dividends amounting to 150 KRW are expected. This corresponds to a dividend yield of 1.37 %.
In which sector is Dae Hwa Pharm Co located?
Dae Hwa Pharm Co is assigned to the 'Health' sector.
Wann musste ich die Aktien von Dae Hwa Pharm Co kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Dae Hwa Pharm Co from 5/1/2024 amounting to 100 KRW, you needed to have the stock in your portfolio before the ex-date on 12/27/2023.
When did Dae Hwa Pharm Co pay the last dividend?
The last dividend was paid out on 5/1/2024.
What was the dividend of Dae Hwa Pharm Co in the year 2023?
In the year 2023, Dae Hwa Pharm Co distributed 150 KRW as dividends.
In which currency does Dae Hwa Pharm Co pay out the dividend?
The dividends of Dae Hwa Pharm Co are distributed in KRW.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Dae Hwa Pharm Co
Our stock analysis for Dae Hwa Pharm Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dae Hwa Pharm Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Dae Hwa Pharm Co Revenue
- Dae Hwa Pharm Co Net Income
- Dae Hwa Pharm Co P/E
- Dae Hwa Pharm Co P/S
- Dae Hwa Pharm Co EBIT
- Dae Hwa Pharm Co Dividend
- Dae Hwa Pharm Co Stocks
- Dae Hwa Pharm Co Market capitalization
- Dae Hwa Pharm Co Debt
- Dae Hwa Pharm Co Liabilities
- Dae Hwa Pharm Co Equity
- Dae Hwa Pharm Co AAQS
- Dae Hwa Pharm Co Employees
- Dae Hwa Pharm Co ROE
- Dae Hwa Pharm Co ROA
- Dae Hwa Pharm Co ROCE